BioTheryX
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7966 Arjons Dr Ste D, San Diego, Califor...Phone Number
(914) 490-5425Website
www.biotheryx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About BioTheryX
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with cancer and other diseases.Explore more
BioTheryX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioTheryX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioTheryX had a recent Job posting/layoffs
Product Launch: Get notified when BioTheryX launches new products
Congratulate Masked Content for being promoted to Masked Content at BioTheryX
BioTheryX, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on BioTheryX recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BioTheryX has new funding data
Check if BioTheryX has recently received funding, and reach out quickly before it becomes old news!
Check out if BioTheryX is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined BioTheryX as Masked Content
Find 3 more new buyers
Compare Similar Companies to BioTheryX
Compare insights from companies similar to BioTheryX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioTheryX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioTheryX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioTheryX.
BioTheryX financials insights
Gather financial insights about BioTheryX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$1.1M
2020
Series D
$35M
2021
Series E
$92M
BioTheryX Tech Stack
A closer look at the technologies used by BioTheryX
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Research & Development, Compliance, Legal Affairs
Event
Events
Left Company
Executive Move
New Hire
Executive Move
BioTheryX News & Media
Biotheryx to Present Results from its Phase 1A Dose Escalation Study of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress
SAN DIEGO, May 4, 2026 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase 1A Dose Escalation Study of BTX-9341, a potent...Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that the first patient has been dosed in the dose expansion phase of...Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer
Topline data readout from Phase 1a clinical trial expected in Q1 2026 SAN DIEGO, Nov. 17, 2025 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced...Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer
SAN DIEGO, July 17, 2024 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases, today announced that the first patient has been dosed in...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioTheryX
Sign Up For FreeTo access detailed company insights
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with cancer and other diseases.... Read More
